TY - JOUR
T1 - Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants
AU - Jimenez-Zepeda, Victor H.
AU - Heilman, Raymond L.
AU - Engel, Rodney A.
AU - Carey, Elizabeth J.
AU - Freeman, Ciara
AU - Rakela, Jorge
AU - Mulligan, David C.
AU - Fonseca, Rafael
AU - Stewart, Alexander Keith
PY - 2011/9/15
Y1 - 2011/9/15
N2 - Background. Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell proliferative disorder with a lifelong risk of progression to multiple myeloma or another plasma cell dyscrasia. Despite a high incidence in the general population and an increased relative risk for later malignancy, there are few reports about the clinical course of MGUS or risk profile in long-term immunosuppressed patients. Methods. We reviewed 1593 solid organ transplant patients and reported the frequency and outcomes of patients with MGUS identified pretransplant. Results. Polyclonal gammopathy pretransplant is common with 17% of all patients and as many as 75% of liver transplant candidates having increased globulins.However, a monoclonal immunoglobulin was identified in only 3% of all solid organ transplant patients pretransplant (n=34). Importantly, in these 34 patients, no cases of progression to multiple myeloma, amyloid, or lymphoma were observed during immune suppression, and there was no association between posttransplant lymphoproliferative disorders and pretransplant MGUS. Death in MGUS patients was not associated with progression of the monoclonal clone or development of posttransplant lymphoproliferative disorders or other malignancy. Conclusion. In conclusion, routine testing for MGUS before transplantation is not prognostic nor a contraindication to transplant, and therefore, it is not recommended.
AB - Background. Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell proliferative disorder with a lifelong risk of progression to multiple myeloma or another plasma cell dyscrasia. Despite a high incidence in the general population and an increased relative risk for later malignancy, there are few reports about the clinical course of MGUS or risk profile in long-term immunosuppressed patients. Methods. We reviewed 1593 solid organ transplant patients and reported the frequency and outcomes of patients with MGUS identified pretransplant. Results. Polyclonal gammopathy pretransplant is common with 17% of all patients and as many as 75% of liver transplant candidates having increased globulins.However, a monoclonal immunoglobulin was identified in only 3% of all solid organ transplant patients pretransplant (n=34). Importantly, in these 34 patients, no cases of progression to multiple myeloma, amyloid, or lymphoma were observed during immune suppression, and there was no association between posttransplant lymphoproliferative disorders and pretransplant MGUS. Death in MGUS patients was not associated with progression of the monoclonal clone or development of posttransplant lymphoproliferative disorders or other malignancy. Conclusion. In conclusion, routine testing for MGUS before transplantation is not prognostic nor a contraindication to transplant, and therefore, it is not recommended.
KW - Monoclonal gammopathy of undetermined significance
KW - Multiple myeloma
KW - Posttransplant lymphoproliferative disorders
KW - Serum protein electrophoresis
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=80052422338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052422338&partnerID=8YFLogxK
U2 - 10.1097/TP.0b013e318225db2c
DO - 10.1097/TP.0b013e318225db2c
M3 - Article
C2 - 21712755
AN - SCOPUS:80052422338
SN - 0041-1337
VL - 92
SP - 570
EP - 574
JO - Transplantation
JF - Transplantation
IS - 5
ER -